Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05612100 | Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients | active not recruiting | — | 169 | Mayo ClinicOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07716644 | Breast Lump Clipping Methods Comparison(BLC) | active not recruiting | N/A | 50 | University of FaisalabadOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03414658 | The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | active not recruiting | Phase 2 | 100 | Adrienne G. WaksOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06758102 | Dance Study for Post-surgical Pain in Breast Cancer Survivors | active not recruiting | N/A | 28 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07710716 | A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients(CATTALYST) | active not recruiting | — | 3,000 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT02792114 | T-Cell Therapy for Advanced Breast Cancer | active not recruiting | Phase 1 | 186 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04115306 | Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer(Dauntless-1) | active not recruiting | Phase 1 / Phase 2 | 61 | Phoenix Molecular DesignsINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05633979 | Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer | active not recruiting | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05754528 | Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance(REaCT-TEMPO) | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT02276443 | Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | active not recruiting | N/A | 798 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02411656 | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | active not recruiting | Phase 2 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02912312 | Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer | active not recruiting | Phase 2 | 805 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06533059 | A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | active not recruiting | Phase 1 | 110 | Alterome Therapeutics, Inc.INDUSTRY | 8 | Jul 15, 2026 | clinicaltrials |
| NCT07692464 | Training On Self-Breast Examination Using Visual Breast Examination Materials For İlliterate Women. | active not recruiting | N/A | 156 | Inonu UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07704801 | CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer(OCDMBC) | active not recruiting | — | 300 | Sohag UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT01505400 | Integrated Molecular Profiling in Advanced Cancers Trial(IMPACT) | active not recruiting | — | 3,026 | University Health Network, TorontoOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer(OlympiA) | active not recruiting | Phase 3 | 1,837 | AstraZenecaINDUSTRY | 24 | Jul 14, 2026 | clinicaltrials |
| NCT02240472 | Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial. | active not recruiting | N/A | 2,766 | Karolinska InstitutetOTHER | 3 | Jul 14, 2026 | clinicaltrials |
| NCT04039230 | Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. | active not recruiting | Phase 1 / Phase 2 | 75 | Massachusetts General HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05223322 | Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction(DECODE) | active not recruiting | N/A | 80 | Medical College of WisconsinOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06557148 | A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer | active not recruiting | — | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07342309 | Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States | active not recruiting | — | 7,933 | Boehringer IngelheimINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07386938 | A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer | active not recruiting | Phase 3 | 246 | R-PharmINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03083288 | Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer | active not recruiting | Phase 1 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03861975 | Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening | active not recruiting | N/A | 100 | Massachusetts General HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04174742 | Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer | active not recruiting | — | 115 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04443348 | Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | active not recruiting | Phase 2 | 120 | Laura M. Spring, MDOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05787587 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 216 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06112379 | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | active not recruiting | Phase 3 | 1,902 | AstraZenecaINDUSTRY | 26 | Jul 13, 2026 | clinicaltrials |
| NCT01463072 | Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer | active not recruiting | Phase 2 | 40 | City of Hope Medical CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT01943695 | Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer | active not recruiting | N/A | 144 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04711824 | Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases(SOLARA) | active not recruiting | Phase 1 / Phase 2 | 41 | Colette ShenOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05101096 | Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors(ASCENT-J02) | active not recruiting | Phase 1 / Phase 2 | 135 | Gilead SciencesINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05458674 | Tucatinib+Trastuzumab+Eribulin in HER2+ MBC | active not recruiting | Phase 2 | 17 | Criterium, Inc.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07693361 | Robotic-Assisted Versus Endoscopic-Assisted Axillary Lymph Node Dissection in Breast Cancer | active not recruiting | — | 127 | Guangzhou Women and Children's Medical CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT03747120 | Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] | active not recruiting | Phase 2 | 138 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04567420 | DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)(DARE) | active not recruiting | Phase 2 | 70 | Criterium, Inc.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05607004 | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer(EVANGELINE) | active not recruiting | Phase 2 | 87 | Atossa Therapeutics, Inc.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05703178 | Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia | active not recruiting | Phase 3 | 452 | Northwestern UniversityOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT02605486 | Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) | active not recruiting | Phase 1 / Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05931302 | Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT(GALILEE) | active not recruiting | N/A | 40 | Centre Hospitalier Intercommunal de Toulon La Seyne sur MerOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07626970 | THE IMPACT OF WHATSAPP BASED EX-PLISSIT MODEL SEXUAL COUNSELING ON THE SEXUAL LIVES OF BREAST CANCER SURVIVORS | active not recruiting | N/A | 86 | Karamanoğlu Mehmetbey UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT02623972 | A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer | active not recruiting | Phase 2 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03635632 | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | active not recruiting | Phase 1 | 94 | Baylor College of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05325151 | Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer | active not recruiting | N/A | 874 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05798806 | Predictive Model of Axillary Nodal Status After Neoadjuvant Chemotherapy in Breast Cancer Patients(LNNEO) | active not recruiting | — | 1,950 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06239467 | First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer(PIKture-01) | active not recruiting | Phase 1 | 200 | OnKure, Inc.INDUSTRY | 6 | Jul 6, 2026 | clinicaltrials |
| NCT06764186 | A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain(CAPItana) | active not recruiting | Phase 3 | 101 | AstraZenecaINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 21, 2026source: clinicaltrials